Financial Data and Key Metrics Changes - In Q4 2025, the company reported sales of $751 million, with core sales increasing by 10.8% year-over-year, benefiting from foreign exchange (FX) which added nearly 400 basis points [15][19] - Adjusted EBITDA margin for Q4 was 14.8%, a 90 basis point improvement from the previous year, driven by volume, price, and productivity [16][21] - Adjusted EPS for Q4 was $0.38, up more than 50% from Q4 2024, supported by strong operating profits and share repurchases [13][16] - For the full year 2025, sales reached $2.7 billion, with core sales increasing by 6.5% [17][18] - Adjusted EBITDA for 2025 was up 26%, resulting in a margin of around 14%, a 2-point improvement over 2024 [13][18] Business Line Data and Key Metrics Changes - Specialty Products & Technologies revenue grew nearly 16% year-on-year, with core sales up 10.9% [22] - The orthodontics business, Spark, experienced high single-digit growth, aided by a deferral change [22] - The Equipment and Consumables segment saw core sales increase by 10.7%, with diagnostic core sales up double digits globally [24] Market Data and Key Metrics Changes - The North American diagnostic market returned to growth in the second half of 2025, marking the third consecutive quarter of positive growth across all business lines [31] - The global implant market is estimated to be growing mid-single digits, with the company slightly outperforming this growth in Q4 [70] Company Strategy and Development Direction - The company is focused on a Value Creation Plan aimed at achieving 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth, with a free cash flow conversion target of 100% or better [7][30] - The company is investing in new product development and customer training, with a significant increase in R&D investment in 2025 [8][10] Management's Comments on Operating Environment and Future Outlook - Management noted that the dental market remains slow but stable, with signs of improvement beginning to emerge [31] - The company expects core revenue growth of 2%-4% for 2026, aligning with medium-term financial objectives [14][26] - Management highlighted potential upsides in diagnostics and consumables, while also acknowledging risks related to macroeconomic volatility and the Chinese market [39][40] Other Important Information - The company implemented a $250 million share repurchase program in early 2025, returning over $160 million to shareholders throughout the year [9][25] - The non-GAAP tax rate for Q4 was 30.3%, with expectations for a reduction to approximately 28% in 2026 due to improved profitability [16][29] Q&A Session Summary Question: Can you discuss guidance and potential upsides and risks? - Management indicated that the core guidance for 2026 is 2%-4%, with upsides including momentum in growth and potential improvements in diagnostics and consumables [34][35] - Risks include macroeconomic volatility and uncertainties in the Chinese market [40][41] Question: What are the expectations for the tax rate? - The expected tax rate for 2026 is around 28%, with potential for further reductions depending on U.S. profit improvements and debt management [46][48] Question: What is the status of VBP for ortho and implants? - Management expects a first-round VBP for ortho and a second-round VBP for implants in 2026, but specific timing remains uncertain [51][53] Question: How did the company achieve higher growth in Q4 compared to previous guidance? - Management attributed the growth to a strong performance in the China ortho market and better-than-expected results in implants [59][64] Question: How do new products contribute to growth? - Management noted that while new products are expected to launch in 2026, their impact was not significant in 2025, with growth driven by pricing and market conditions [70][72]

Financial Performance - Q3 FY2025 - Revenue reached $1.74 billion, exceeding guidance by over $60 million[9] - Reported revenue growth was +10.1%[7, 11] - Core revenue growth was +6.1%[7, 16] - EPS was $1.37, a +4% year-over-year increase[7, 9] - Operating margin was 25.1%[7, 9] FY2025 Outlook - Core growth outlook raised to 4.5%[9, 14] - Revenue guidance increased by $150 million at the midpoint[9] - Net Revenue guidance is $6.91 to $6.93 billion[34] - EPS guidance is $5.56 to $5.59[34] Segment Performance - Q3 FY2025 - LDG (Life Sciences and Diagnostics Group) core growth was +14%[18] - ACG (Agilent CrossLab Group) core growth was +5%[18] - AMG (Agilent Molecular Spectroscopy Group) core growth was +7%[18] Revenue Breakdown - Americas accounted for 39% of Agilent's revenue[23] - Europe accounted for 28% of Agilent's revenue[23] - Asia-Pacific accounted for 33% of Agilent's revenue[23]